News

Ethos Cannabis Commences Opioid Use Study With Thomas Jefferson University

Jefferson is seeking participants for the 4-month study

Ethos Cannabis (“Ethos” or the “Company”)  announced today the official launch of an opiate-use study with Sidney Kimmel Medical College  at Thomas Jefferson University (“Jefferson”) which seeks to assess the viability of medical  cannabis as an opioid replacement therapeutic aid. The purpose of this study is to learn if  medical cannabis helps people with chronic pain who currently take opioid pain medication.  Jefferson is hoping to determine if medical cannabis could replace opioids for those struggling  with opioid use disorder or opioid dependency.  

According to the United States Department of Health and Human Services, an estimated 10.1  million people misused opioids in 2019. Specifically, 9.7 million people misused prescription  pain relievers. Medical cannabis shows potential for mitigating opioid dependency, but due to  federal restrictions research on the topic is scarce.  

Jefferson is seeking participants for the 4-month study who are currently diagnosed with chronic pain, have been taking opioids (oxycodone, Percocet, morphine, etc.) for a period longer than  90 days, and are not currently using medical marijuana products. Certain participants will  introduce various medical marijuana products into their treatment plan in a double blinded  fashion and Jefferson researchers will observe the impact of these products on their opiate use  and pain and withdrawal symptoms. All participants will be asked to complete compensated  baseline, daily, weekly, and monthly questionnaires and interviews about their health and opioid  use.  

“We fully appreciate the risk of long-term opioid use including progression to opioid use  disorder,” said Brooke Worster, MD, FACP, and lead researcher from Jefferson. “There is  potential in cannabis as a safer, tolerable therapy to lessen the reliance and impact of opioids.  However, we have minimal quantifiable science to feel comfortable making solid medical  recommendations to patients. This study is an important step in that process, using forms and  strains of cannabis that are common in the marketplace and getting real-time patient  assessments in terms of effective pain relief, side effects, reduction in opioid cravings, and 

withdrawal. We expect to have meaningful data collection over the next 18 months which could  directly translate into clinical practice change.”  

David Clapper, CEO of Ethos, added, “The Pennsylvania legislation that created the Clinical  Registrant (CR) permit program exponentially expanded our ability to do effective, impactful  research in this space. Ethos is thrilled to continue working alongside Jefferson’s dedicated  team to progress our understanding of medical cannabis.”  

Ethos is one of eight Clinical Registrant (CR) permit holders in Pennsylvania that is conducting  research related to medical cannabis. Thomas Jefferson University, Ethos’ designated partner,  is one of the country’s leading medical schools and is certified by the Pennsylvania Department  

of Health (DOH) as an Academic Clinical Research Center (ACRC). Ethos’ dispensaries in  Philadelphia, Montgomeryville and Pittsburgh, PA are all certified under the CR permit and will  be recruiting participants for the study.  

About Ethos Cannabis:  

Ethos Cannabis is a multistate operator with operations in Pennsylvania, Massachusetts and  Maryland. Ethos is developing a leading vertically integrated, retail-focused platform in the Mid Atlantic and East Coast markets of the U.S. This platform serves mainstream consumers while  expanding the health and wellness market through relationships with Thomas Jefferson  University and other academic medical institutions and strategic partnerships. Ethos is  dedicated to helping individuals feel and live better through their experiences with cannabis.  

For more information about Ethos, visit their website at https://www.ethospa.com/.

For more  information about the study, please call 215-503-3013 or email MMJstudy@Jefferson.edu.  

Stay up-to-date!

Get all the news and info straight into your inbox that you need to help grow your business.

Marijuana Retail Report, is a national daily online trade publication serving retailers of marijuana products and accessories. News and information are geared strictly to select retail channels, with distribution limited to licensed collectives, recreational retailers, accessories retailers, and wholesalers.

Newsletter

Stay informed with the most up-to-date industry news to help you grow your business: subscribe to our newsletter below!


To Top